Advertisement

Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?

  • Mariana Rodrigues Pioli
  • Ana Paula de FariaEmail author
Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)
  • 54 Downloads
Part of the following topical collections:
  1. Topical Collection on Antihypertensive Agents: Mechanisms of Drug Action

Abstract

Purpose of Review

To gather data from studies evaluating the pro-inflammatory profile of individuals with resistant hypertension (RH), and bring a clinical update of new and potential complementary therapies to treat inflammation in RH.

Recent Findings

Increases in pro-inflammatory cytokines are related to elevated blood pressure and target organ damage in RH patients. Clinical and experimental studies have shown that some biological therapies, especially TNF-α inhibitors, regulated pro- and anti-inflammatory cytokines associated with improvements in clinical outcomes, although they are not yet reported in RH.

Summary

New emerging therapies to treat inflammation in RH, although promising, are still hypotheses that have not been scientifically confirmed in clinical trials. For this reason, inflammation-target treatments, such as the TNF-α and IL-6 inhibitors, should be encouraged for testing as complementary therapies in RH in order to elucidate their potential benefits.

Keywords

Refractory hypertension Blood pressure Cytokines Inflammation Biological therapies 

Notes

Acknowledgments

Mariana Rodrigues Pioli acknowledges the Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil.

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53–90.  https://doi.org/10.1161/HYP.0000000000000084.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50(4):723–8.  https://doi.org/10.1161/HYPERTENSIONAHA.107.093120.CrossRefPubMedGoogle Scholar
  3. 3.
    Belen E, Sungur A, Sungur MA, Erdoğan G. increased neutrophil to lymphocyte ratio in patients with resistant hypertension. J Clin Hypertens (Greenwich). 2015;17(7):532–7.  https://doi.org/10.1111/jch.12533.CrossRefGoogle Scholar
  4. 4.
    Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98(1):121–8.  https://doi.org/10.1016/j.amjcard.2006.01.059.CrossRefPubMedGoogle Scholar
  5. 5.
    Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006;48(6):1050–7.  https://doi.org/10.1161/01.HYP.0000248135.97380.76.CrossRefPubMedGoogle Scholar
  6. 6.
    Sabbatini AR, Faria AP, Barbaro NR, Gordo WM, Modolo RG, Pinho C, et al. Deregulation of adipokines related to target organ damage on resistant hypertension. J Hum Hypertens. 2014;28(6):388–92.  https://doi.org/10.1038/jhh.2013.118.CrossRefPubMedGoogle Scholar
  7. 7.
    •• Chen J, Bundy JD, Hamm LL, Hsu CY, Lash J, Miller ER, et al. Inflammation and apparent treatment-resistant hypertension in patients with chronic kidney disease. Hypertension. 2019;73(4):785–93.  https://doi.org/10.1161/HYPERTENSIONAHA.118.12358 This study indicates that inflammatory biomarkers such as IL-6, TNF-α, and TGF-β are associated with apparent treatment-resistant hypertension.CrossRefPubMedGoogle Scholar
  8. 8.
    • Abdelrahman AM, Al Suleimani YM, Ashique M, Manoj P, Ali BH. Effect of infliximab and tocilizumab on fructose-induced hyperinsulinemia and hypertension in rats. Biomed Pharmacother. 2018;105:182–6.  https://doi.org/10.1016/j.biopha.2018.05.118 Infliximab and tocilizumab reduce mean arterial pressure and heart hate, but only infliximab reduces systolic blood pressure.CrossRefPubMedGoogle Scholar
  9. 9.
    Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum Dis. 2010;69(7):1342–5.  https://doi.org/10.1136/ard.2009.124180.CrossRefPubMedGoogle Scholar
  10. 10.
    Yoshida S, Takeuchi T, Kotani T, Yamamoto N, Hata K, Nagai K, et al. Infliximab, a TNF-α inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens. 2014;28(3):165–9.  https://doi.org/10.1038/jhh.2013.80.CrossRefPubMedGoogle Scholar
  11. 11.
    Barbaro NR, Harrison DG. Markers or makers: inflammatory cytokines in treatment-resistant hypertension. Hypertension. 2019;73(4):767–9.  https://doi.org/10.1161/HYPERTENSIONAHA.119.12604.CrossRefPubMedGoogle Scholar
  12. 12.
    Mikolajczyk TP, Guzik TJ. Adaptive immunity in hypertension. Curr Hypertens Rep. 2019;21(9):68.  https://doi.org/10.1007/s11906-019-0971-6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51(5):1345–51.  https://doi.org/10.1161/HYPERTENSIONAHA.107.102152.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 2012;59(1):136–44.  https://doi.org/10.1161/HYPERTENSIONAHA.111.173328.CrossRefPubMedGoogle Scholar
  15. 15.
    Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500–7.  https://doi.org/10.1161/HYPERTENSIONAHA.109.145094.CrossRefPubMedGoogle Scholar
  16. 16.
    Kirabo A, Fontana V, de Faria AP, Loperena R, Galindo CL, Wu J, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124(10):4642–56.  https://doi.org/10.1172/JCI74084.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, et al. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens. 2011;25(2):73–9.  https://doi.org/10.1038/jhh.2010.91.CrossRefPubMedGoogle Scholar
  18. 18.
    Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149–53.  https://doi.org/10.1161/01.cir.101.18.2149.CrossRefPubMedGoogle Scholar
  19. 19.
    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–72.  https://doi.org/10.1161/01.cir.101.15.1767.CrossRefPubMedGoogle Scholar
  20. 20.
    Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, Fonseca FH, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press. 2015;24(1):7–13.  https://doi.org/10.3109/08037051.2014.940710.CrossRefPubMedGoogle Scholar
  21. 21.
    Barbaro NR, de Araújo TM, Tanus-Santos JE, Anhê GF, Fontana V, Moreno H. Vascular damage in resistant hypertension: TNF-Alpha Inhibition Effects on Endothelial Cells. Biomed Res Int. 2015;2015:631594.  https://doi.org/10.1155/2015/631594.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    de Faria AP, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013;36(12):1067–72.  https://doi.org/10.1038/hr.2013.92.CrossRefPubMedGoogle Scholar
  23. 23.
    de Haro MC, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225–30.  https://doi.org/10.1038/jhh.2012.29.CrossRefGoogle Scholar
  24. 24.
    Catharina AS, Modolo R, Ritter AMV, Sabbatini AR, Lopes HF, Moreno Junior H, et al. Metabolic syndrome-related features in controlled and resistant hypertensive subjects. Arq Bras Cardiol. 2018;110(6):514–21.  https://doi.org/10.5935/abc.20180076.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:71.  https://doi.org/10.3389/fendo.2013.00071.CrossRefGoogle Scholar
  26. 26.
    Knights AJ, Funnell AP, Pearson RC, Crossley M, Bell-Anderson KS. Adipokines and insulin action: a sensitive issue. Adipocyte. 2014;3(2):88–96.  https://doi.org/10.4161/adip.27552.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Li J, Huang M, Shen X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with hyperglycemic crisis. J Diabetes Complicat. 2014;28(5):662–6.  https://doi.org/10.1016/j.jdiacomp.2014.06.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Schmidt FM, Weschenfelder J, Sander C, Minkwitz J, Thormann J, Chittka T, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015;10(3):e0121971.  https://doi.org/10.1371/journal.pone.0121971.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    •• Faria AP, Ritter AMV, Gasparetti CS, Correa NB, Brunelli V, Almeida A, et al. A proposed inflammatory score of circulating cytokines/adipokines associated with resistant hypertension, but dependent on obesity parameters. Arq Bras Cardiol. 2019;112(4):383–9.  https://doi.org/10.5935/abc.20190032 This study suggests an integrated measure of circulating cytokines/adipokines related to resistant hypertension.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Rosa AC, Rattazzi L, Miglio G, Collino M, Fantozzi R. Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes. Inflamm Res. 2012;61(4):311–7.  https://doi.org/10.1007/s00011-011-0412-8.CrossRefPubMedGoogle Scholar
  31. 31.
    Brili S, Tousoulis D, Antoniades C, Vasiliadou C, Karali M, Papageorgiou N, et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J Am Coll Cardiol. 2008;51(7):742–9.  https://doi.org/10.1016/j.jacc.2007.10.036.CrossRefPubMedGoogle Scholar
  32. 32.
    Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42(5):905–10.  https://doi.org/10.1016/s0735-1097(03)00846-5.CrossRefPubMedGoogle Scholar
  33. 33.
    Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2013;50(2):89–99.  https://doi.org/10.1159/000345243.CrossRefPubMedGoogle Scholar
  34. 34.
    Bendtzen K, Hansen PR, Rieneck K, Group SAS. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol. 2003;134(1):151–8.  https://doi.org/10.1046/j.1365-2249.2003.02249.x.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117(17):2253–61.  https://doi.org/10.1161/CIRCULATIONAHA.107.748640.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Sandoo A, Panoulas VF, Toms TE, Smith JP, Stavropoulos-Kalinoglou A, Metsios GS, et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011;25(11):699–702.  https://doi.org/10.1038/jhh.2011.36.CrossRefPubMedGoogle Scholar
  37. 37.
    Desai RJ, Solomon DH, Schneeweiss S, Danaei G, Liao KP, Kim SC. Tumor necrosis factor-α inhibitor use and the risk of incident hypertension in patients with rheumatoid arthritis. Epidemiology. 2016;27(3):414–22.  https://doi.org/10.1097/EDE.0000000000000446.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tran LT, MacLeod KM, McNeill JH. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem. 2009;330(1-2):219–28.  https://doi.org/10.1007/s11010-009-0136-z.CrossRefPubMedGoogle Scholar
  39. 39.
    Huang B, Cheng Y, Usa K, Liu Y, Baker MA, Mattson DL, et al. Renal tumor necrosis factor α contributes to hypertension in dahl salt-sensitive rats. Sci Rep. 2016;6:21960.  https://doi.org/10.1038/srep21960.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, et al. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2010;56(4):643–9.  https://doi.org/10.1161/HYPERTENSIONAHA.110.157685.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Haugen E, Täng MS, Isic A, Andersson B, Fu M. TNFalpha antagonist upregulates interleukin-6 in rats with hypertensive heart failure. Int J Cardiol. 2008;130(1):64–8.  https://doi.org/10.1016/j.ijcard.2007.08.047.CrossRefPubMedGoogle Scholar
  42. 42.
    Sriramula S, Cardinale JP, Francis J. Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS One. 2013;8(5):e63847.  https://doi.org/10.1371/journal.pone.0063847.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Song XA, Jia LL, Cui W, Zhang M, Chen W, Yuan ZY, et al. Inhibition of TNF-α in hypothalamic paraventricular nucleus attenuates hypertension and cardiac hypertrophy by inhibiting neurohormonal excitation in spontaneously hypertensive rats. Toxicol Appl Pharmacol. 2014;281(1):101–8.  https://doi.org/10.1016/j.taap.2014.09.004.CrossRefPubMedGoogle Scholar
  44. 44.
    Filho AG, Kinote A, Pereira DJ, Rennó A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700(1-3):201–9.  https://doi.org/10.1016/j.ejphar.2012.11.059.CrossRefPubMedGoogle Scholar
  45. 45.
    •• de Faria AP, Moreno H. Effects of the TNF-alpha inhibiton on hemodynamic parameters in resistant hypertension. 2016. https://clinicaltrials.gov/ct2/show/NCT02743390. Accessed August, 10 2019. This study evaluates whether an acute dose of infliximab (controlled by placebo) reduces blood pressure in RH subjects.
  46. 46.
    Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, et al. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Arch Pharm Res. 2015;38(5):575–84.  https://doi.org/10.1007/s12272-015-0569-8.CrossRefPubMedGoogle Scholar
  47. 47.
    • Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, et al. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol. 2016;173(4):752–65.  https://doi.org/10.1111/bph.13230 This study suggests that the inflammasome/IL-1β pathway is a therapeutic target in hypertension.CrossRefPubMedGoogle Scholar
  48. 48.
    • Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, et al. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. 2019;115(4):776–87.  https://doi.org/10.1093/cvr/cvy252 This study suggests that inhibition of NLRP3 inflammasome by the MCC950 molecule is an antihypertensive strategy.CrossRefPubMedGoogle Scholar
  49. 49.
    Henao-Mejia J, Elinav E, Strowig T, Flavell RA. Inflammasomes: far beyond inflammation. Nat Immunol. 2012;13(4):321–4.  https://doi.org/10.1038/ni.2257.CrossRefPubMedGoogle Scholar
  50. 50.
    Karmakar M, Katsnelson M, Malak HA, Greene NG, Howell SJ, Hise AG, et al. Neutrophil IL-1β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol. 2015;194(4):1763–75.  https://doi.org/10.4049/jimmunol.1401624.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.  https://doi.org/10.1016/S0140-6736(09)60566-3.CrossRefPubMedGoogle Scholar
  52. 52.
    Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.  https://doi.org/10.1016/S0140-6736(10)62039-9.CrossRefPubMedGoogle Scholar
  53. 53.
    Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.  https://doi.org/10.1056/NEJMoa1402670.CrossRefPubMedGoogle Scholar
  54. 54.
    Kampmann U, Mathiassen ON, Christensen KL, Buus NH, Bjerre M, Vase H, et al. Effects of renal denervation on insulin sensitivity and inflammatory markers in nondiabetic patients with treatment-resistant hypertension. J Diabetes Res. 2017;2017:6915310.  https://doi.org/10.1155/2017/6915310.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Eikelis N, Hering D, Marusic P, Sari C, Walton A, Phillips S, et al. The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension. Int J Cardiol. 2015;188:96–8.  https://doi.org/10.1016/j.ijcard.2015.04.041.CrossRefPubMedGoogle Scholar
  56. 56.
    • Eikelis N, Hering D, Marusic P, Duval J, Hammond LJ, Walton AS, et al. The Effect of renal denervation on plasma adipokine profile in patients with treatment resistant hypertension. Front Physiol. 2017;8:369.  https://doi.org/10.3389/fphys.2017.00369 This study was the first to associate renal denervation procedure with adipokines in resistant hypertensive patients.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, FCM 10 BuildingSchool of Medical Sciences - University of Campinas (FCM-UNICAMP)CampinasBrazil

Personalised recommendations